Präsentationen
Aktie
Aktueller Finanzbericht
News
Neueste
Tweets
vor 3 Tage 3 Stunden
@MorphoSys
We are pleased that our licensing partner @GSK is continuing to explore an antibody generated by MorphoSys as a pot… https://t.co/e96LSsV4st
vor 1 Woche 11 Stunden
@MorphoSys
MorphoSys is proud to support #RareDiseaseDay on February 28. More than 300 million people are living with a rare d… https://t.co/ZoT7V4xc1P
vor 1 Woche 1 Tag
@MorphoSys
We are participating in the 10th Annual SVB Leerink Global Healthcare Conference this week. Join our CEO Jean-Paul… https://t.co/8Hy61m3RZe
vor 4 Wochen 1 Tag
@MorphoSys
WE ARE MorphoSys AND WE WILL commit to helping improve the lives of people impacted by cancer. On today’s… https://t.co/oJIqYFPmNf
vor 1 Monat 2 Wochen
@MorphoSys
8m • 8 minutes ago
Our footprint in Boston doubled in 2020 to support our rapid growth. Join a team of industry exp… https://t.co/XKNRhM4bj1
vor 1 Monat 3 Wochen
@MorphoSys
Join our CEO Jean-Paul Kresst at #JPM21 to hear a MorphoSys 2021 strategic update and learn about our clinical tria… https://t.co/X5aP486RCp
vor 1 Monat 4 Wochen
@MorphoSys
Welcome Sung Lee, our new CFO, as of Feb. 2. “Sung has demonstrated tremendous talent in driving financial performa… https://t.co/l4n5I2gDOt
vor 2 Monate 3 Wochen
@MorphoSys
Diffuse large B-cell lymphoma (#DLBCL) is a fast-growing cancer affecting B-cells, a type of lymphocyte. Cancerous… https://t.co/4hEnDiCuzr
vor 2 Monate 4 Wochen
@MorphoSys
Preliminary safety and efficacy data from Phase 1b #firstMIND trial in patients with a certain type of #bloodcancer… https://t.co/aHFD9PpwHa
vor 2 Monate 4 Wochen
@MorphoSys
We’re sharing our scientific and clinical advances at @ASH_hematology’s Virtual Meeting. Visit our virtual booth… https://t.co/JJsyeSE3Ga
Investorenkontakt
Dr. Julia Neugebauer
Senior Director Investor Relations
Telefon +49 89 89927 179
Myles Clouston
Senior Director, Head of US Investor Relations
Telefon +1 857 772 0240
Medienkontakt
Thomas Biegi
Vice President, Head of Corporate Communications
Telefon +49 89 89927 26079
Sophie Petersen
Senior Specialist Corporate Communications
Telefon +49 89 89927 26033
Fax: +49 89 89927 526033